Home > News > DNA Sequence Variants in LOXL1 and Pseudoexfoliation Glaucoma
Glaucoma
Read Time: 5 mins

DNA Sequence Variants in LOXL1 and Pseudoexfoliation Glaucoma

Published Online: February 17th 2011 US Ophthalmic Review, 2007,3:18-20 DOI: http://doi.org/10.17925/USOR.2007.03.00.18
Authors: Bao Jian Fan, Janey L Wiggs
Quick Links:
Article
Article Information
Article:

Glaucoma is a group of diseases resulting in an irreversible degeneration of the optic nerve. It is one of the leading causes of blindness worldwide, estimated to affect more than 60 million people by 2010.1 Pseudoexfoliation syndrome (PXFS) results in the deposition of microfibrillar material throughout the eye, with over 50% of cases developing glaucoma. Primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXFG) are the most common forms of glaucoma. Genetic factors play an important role in the development of these disorders.2–5 Fourteen chromosomal loci have been designated GLC1A to GLC1N for POAG.2,6 From these loci, three genes have been identified as causative factors for POAG. Mutations in the MYOC gene at GLC1A primarily cause high-tension glaucoma (HTG).7,8 The OPTN gene at GLC1E appears to contribute to normal-tension glaucoma (NTG).9,10 The WDR36 gene at GLC1G is considered to be a modifier gene affecting both HTG11–13 and NTG patients.11,13 However, mutations in these genes together only account for fewer than 10% of all POAG cases.2 Collectively, these results underscore the genetic complexity of POAG and the need for the identification of genes that confer significant susceptibility.

Genetics of Pseudoexfoliation Glaucoma
PXFS and associated glaucoma also appear to be a genetically complex disease. A genome-wide scan with 1,000 microsatellite markers in a Finnish family with PXFS suggested linkage to 18q12.1–21.33 and regions of chromosomes 2q, 17q, and 19q.4 Loss of heterozygosity has been reported on chromosomes 13q12.11, 7p13, 7q21.3, and 7q21.11 in patients with PXFS.14,15 Recently, a genome-wide association study identified a strong association of the LOXL1 gene with PXFG in patients from Iceland and Sweden.5 This association has been replicated in our study of a US clinic-based population with broad ethnic diversity16 and in other studies using Caucasian,17–23 Indian,24 and Japanese25–29 ethnic populations. These studies indicate that LOXL1 is a major gene associated with PXFG, accounting for up to 99% of PXFG cases in most populations.

Initial Association Studies of LOXL1 with Pseudoexfoliation Glaucoma
The initial genome-wide association study using 304,250 single nucleotide polymorphisms (SNPs) identified a strong association of SNP rs2165241 in the first intron of LOXL1 with PXFG in Icelandic patients.5 This strong association was replicated in Swedish patients with PXFG.5 Further genotyping identified a strong association of two non-synonymous SNPs (rs1048661 and rs3825942) in the first exon of LOXL1 with PXFG in both Icelandic and Swedish patients (see Table 1).5 The intronic SNP rs2165241 was no longer significant after adjusting for both non-synonymous SNPs. SNP rs1048661 (R141L) changes an arginine to a leucine and rs3825942 (G153D) changes a glycine to an asparagine in the LOXL1 protein. Compared with allele T, allele G of rs1048661 has a 2.56- and 2.39-fold increased risk of developing PXFG in Icelandic and Swedish populations, respectively (see Table 1). For rs3825942, relative to allele A, allele G confers a 13.23- and 27.28-fold increased risk of developing PXFG in Icelandic and Swedish populations, respectively (see Table 1). Jointly, these two SNPs accounted for more than 99% of all PXFG cases in these populations.5

Follow-up Association Studies of LOXL1 with Pseudoexfoliation Glaucoma
Replication of these initial results in other major populations was important because the Nordic population has a relatively limited gene pool and a high prevalence of PXFS and PXFG.30 Table 1 summarizes all of the association studies of LOXL1 with PXFG in different populations published to date.5,16–29 We have replicated the association of LOXL1 with PXFG in a US clinic-based population with broad ethnic diversity.16 Our studied population was predominantly Caucasian patients of European ancestry, but the sample also included 6% African-Americans. Intriguingly, unlike the highly significant association found in the previous study,5 rs1048661 (p=0.0031) was much less significant than rs3825942 (p=1.3×10-13) in our study.16 Haplotype analysis suggested that the effect of rs3825942 on PXFG was independent of rs1048661, whereas rs1048661 was no longer associated with PXFG after controlling for rs3825942.16 Most importantly, the risk allele of rs1048661 associated with PXFG in Japanese studies (allele T)25–29 is different from that in other populations (allele G),5,16–24 which argues that SNP rs1048661 itself does not contribute to the disease. Taken together, it appears that rs3825942 is the only non-synonymous SNP in the LOXL1 gene that independently contributes to PXFG, and the contribution of rs1048661 appears to be less significant. The apparent association of rs1048661 with PXFG in some populations is likely to be the result of linkage disequilibrium with rs3825942.

The risk allele frequency of rs3825942 is extremely high in patients with PXFG in most of the populations studied (92–99%) (see Table 1). However, the risk allele of rs3825942 is also prevalent in control samples, with a frequency of over 85% in most populations, indicating that additional genetic and/or environmental factors could be involved in the development of PXFG. In some populations, such as the Australian population, the frequency of the rs3825942 risk allele is much higher than the disease prevalence, suggesting a reduced penetrance in these populations.21 This result further suggests that additional factors, both genetic and environmental, and potentially additive and protective, could influence the development of this complex disorder. It has been reported that homocysteine levels are elevated in the aqueous humor, tear fluid, and plasma of patients with PXFG.31–33 These studies indicate that hyperhomocysteinemia may be associated with pseudoexfoliation and may contribute to the vascular impairment and the alteration of extracellular matrix observed in patients with PXFG. The genes that affect homocysteine levels may be secondary factors that could contribute to PXFG.

Functional Studies of LOXL1
LOXL1 is a member of the lysl oxidase family of proteins that catalyze the polymerization of tropoelastin to form the mature elastin polymer.34 Elastin fibers are a major component of many structures in the eye, including those that could be involved in PXFG, such as the extracellular matrix of the trabecular meshwork and the lamina cribrosa of the optic nerve.35,36 LOXL1 is also involved in elastin homeostasis and renewal, and participates in spatially organizing elastogenesis at sites of elastin deposition. Binding of LOXL1 to the elastin scaffold is required for this function.37 The LOX family has five members, including the LOX protein and the LOX-like proteins (LOXL1 to LOXL4). All of these LOX family members have seven exons with a similar structure. Exons 2 to 6 show strong homology and encode the C-terminal catalytic domain of these proteins. Both rs1048661 (R141L) and rs3825942 (G153D) are located in the N-terminal pro-peptide, which may have a role in directing the LOXL1 protein to sites of elastogenesis, but is unlikely to affect the catalytic activity of the protein.37 However, the biological effect of these missense alterations on the expression of LOXL1 in ocular tissues has not been determined. The exact role of LOXL1 in the eye is still unclear, and further investigations are ongoing. As the catalytic domains are located in the highly conserved C-terminal of the LOXL1 protein, it is important to further investigate the association of this portion of LOXL1 with PXFG.

Conclusions and Future Prospects
In summary, a strong association of LOXL1 with PXFG has been identified and replicated in several major populations. These studies indicate that LOXL1 is a major gene associated with PXFG, accounting for 99% of PXFG cases in most populations. The difference in the risk allele of rs1048661 associated with PXFG between Japanese and other populations suggests that SNP rs3825942 is most likely to be responsible for disease development. However, the biological effect of this missense alteration (G153D) on the expression of LOXL1 in ocular tissues remains to be determined, and the precise role of LOXL1 in the eye is still under investigation. It is not yet known whether the G153D missense change creates a gain of function or loss of function of the protein, or whether this SNP is in linkage disequilibrium with other DNA sequence variants that affect the expression of the gene. The high prevalence of the rs3825942 risk allele in control populations and the apparently variable penetrance of the condition in some populations suggest that additional genetic factors and/or environmental exposures that may function as additive or protective factors could be involved in the development of this complex disease. Other proteins that are involved in the maintenance of elastin fibers and the alteration of extracellular matrix, such as the genes that determine homocysteine levels, are good candidates for secondary genetic factors that could contribute to this common blinding disease.

Article Information:
Received

2011-02-17T00:00:00

References

  • 1. Quigley HA, Broman AT, Br J Ophthalmol, 2006;90:262–7.
  • 2. Fan BJ,Wang DY, Lam DS, Pang CP, Clin Biochem, 2006;39:249–58.
  • 3. van Koolwijk LM, Despriet DD, van Duijn CM, et al., Invest Ophthalmol Vis Sci, 2007;48:3669–76.
  • 4. Lemmela S, Forsman E, Sistonen P, et al., Invest Ophthalmol Vis Sci, 2007;48: 4136–42.
  • 5. Thorleifsson G, Magnusson KP, Sulem P, et al., Science, 2007;317:1397–1400.
  • 6. Wang DY, Fan BJ, Chua JK, et al., Invest Ophthalmol Vis Sci, 2006;47:5315–21.
  • 7. Stone EM, Fingert JH, Alward WL, et al., Science, 1997;275: 668–70.
  • 8. Fan BJ, Leung DY,Wang DY, et al., Arch Ophthalmol, 2006;124:102–6.
  • 9. Rezaie T, Child A, Hitchings R, et al., Science, 2002;295:1077–9.
  • 10. Leung YF, Fan BJ, Lam DS, et al., Invest Ophthalmol Vis Sci, 2003;44:3880–84.
  • 11. Monemi S, Spaeth G, DaSilva A, et al.,Hum Mol Genet, 2005;14:725–33.
  • 12. Hauser MA, Allingham RR, Linkroum K, et al., Invest Ophthalmol Vis Sci, 2006;47:2542–6.
  • 13. Pasutto F, Mardin CY, Michels-Rautenstrauss K, et al., Invest Ophthalmol Vis Sci, 2008;49:270–74.
  • 14. Kozobolis VP, Detorakis ET, Sourvinos G, et al., Invest Ophthalmol Vis Sci, 1999;40:1255–60.
  • 15. Zalewska R, Pepinski W, Smolenska-Janica D, et al., Mol Vis, 2003;9:257–61.
  • 16. Fan BJ, Pasquale L, Grosskreutz CL, et al., BMC Med Genet, 2008;9:5.
  • 17. Fingert JH, Alward WL, Kwon YH, et al., Am J Ophthalmol, 2007;144:974–5.
  • 18. Challa P, Schmidt S, Liu Y, et al., Mol Vis, 2008;14:146–9.
  • 19. Yang X, Zabriskie NA, Hau VS, et al., Cell Cycle, 2008;7:521–4.
  • 20. Aragon-Martin JA, Ritch R, Liebmann J, et al., Mol Vis, 2008;14:533–41.
  • 21. Hewitt AW, Sharma S, Burdon KP, et al., Hum Mol Genet, 2008;17:710–16.
  • 22. Pasutto F, Krumbiegel M, Mardin CY, et al., Invest Ophthalmol Vis Sci, 2008;49:1459–63.
  • 23. Mossböck G, Renner W, Faschinger C, et al., Mol Vis, 2008;14:857–61.
  • 24. Ramprasad VL, George R, Soumittra N, et al., Mol Vis, 2008;14: 318–22.
  • 25. Hayashi H, Gotoh N, Ueda Y, et al., Am J Ophthalmol, 2008;145:582–5.
  • 26. Ozaki M, Lee KY, Vithana EN, et al., Invest Ophthalmol Vis Sci, 2008;49:3976–80.
  • 27. Mori K, Imai K, Matsuda A, et al., Mol Vis, 2008;14:1037–40.
  • 28. Mabuchi F, Sakurada Y, Kashiwagi K, et al., Mol Vis, 2008;14: 1303–8.
  • 29. Fuse N, Miyazawa A, Nakazawa T, et al., Mol Vis, 2008;14:1338–43.
  • 30. Wiggs JL, Arch Ophthalmol, 2008;126:420–21.
  • 31. Bleich S, Roedl J, Von Ahsen N, et al., Am J Ophthalmol, 2004;138:162–4.
  • 32. Roedl JB, Bleich S, Reulbach U, et al., J Glaucoma, 2007; 16:234–9.
  • 33. Altintas O, Maral H, Yuksel N, et al., Graefes Arch Clin Exp Ophthalmol, 2005;243:677–83.
  • 34. Liu X, Zhao Y, Gao J, et al., Nat Genet, 2004;36:178–82.
  • 35. Acott TS, Kelley MJ, Exp Eye Res, 2008;86:543–61.
  • 36. Urban Z, Agapova O, Hucthagowder V, et al., Invest Ophthalmol Vis Sci, 2007;48:3209–15.
  • 37. Thomassin L,Werneck CC, Broekelmann TJ, et al., J Biol Chem, 2005;280:42848–55.
  • Further Resources

    Share this Article
    Related Content In Glaucoma
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72